Phase 3 AMPLITUDE Trial Shows Niraparib-Abiraterone Combination Improves Outcomes in HRR-Deficient Metastatic Prostate Cancer
核心洞察
The Phase 3 AMPLITUDE trial published in Nature Medicine demonstrates clinical benefit of combining niraparib with abiraterone acetate plus prednisone in patients with metastatic hormone-sensitive prostate cancer (搜索) harboring HRR (搜索) gene alterations.
The targeted triplet therapy significantly improved radiographic progression-free survival, with hazard ratios of 0.52 for BRCA1 (搜索)/2 patients and 0.63 for the intention-to-treat population.
This landmark study represents the first targeted triplet therapy to show benefit for HRR (搜索)-deficient tumors in the hormone-sensitive disease stage, making a strong case for upfront genomic sequencing.
The Phase 3 AMPLITUDE trial has demonstrated significant clinical benefit from combining the PARP (搜索) inhibitor niraparib with abiraterone acetate plus prednisone (AAP) in patients with metastatic hormone-sensitive prostate cancer (搜索) (mHSPC) harboring homologous recombination repair (HRR (搜索)) gene alterations, according to results published in Nature Medicine.
Landmark Results for Precision Oncology
The randomized phase 3 trial showed that adding niraparib to abiraterone increased outcomes in HRR (搜索)-altered mHSPC prostate cancer patients. Radiographic progression-free survival (RPFS) was significantly improved, with a hazard ratio of 0.52 (P < 0.0001) for patients with BRCA1 (搜索)/2 alterations and 0.63 (P = 0.0001) for the intention-to-treat population.
"This landmark study demonstrates the clinical benefit of combining niraparib with abiraterone acetate plus prednisone (AAP) in patients with metastatic hormone-sensitive prostate cancer (搜索) (mHSPC) harboring homologous recombination repair (HRR (搜索)) gene alterations," said Fei Shen, Director and Global Compound Development Team Leader at Johnson & Johnson.
First Targeted Triplet Therapy Success
The AMPLITUDE trial represents a significant milestone as the first study to exhibit benefit of a targeted triplet therapy for HRR (搜索)-deficient tumors in the hormone-sensitive disease stage. Dr. Eleni Efstathiou, Genitourinary Oncology Section Chief at Houston Methodist (搜索), emphasized the transformative nature of these findings.
"In the past 10 years we have come a long way in developing treatment for hormone naive advanced prostate cancer. We were literally just using ADT before 2015," Efstathiou noted. "This landmark trial is the first to exhibit benefit of a targeted triplet therapy for HRR (搜索) deficient tumors in this disease stage. It makes the strongest case for upfront genomic sequencing."
Implications for Clinical Practice
The study's results strengthen the case for implementing upfront genomic sequencing in metastatic prostate cancer patients to identify those who could benefit from this targeted approach. The combination therapy specifically targets patients with HRR (搜索) gene alterations, representing a precision medicine approach to treating this patient population.
Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, highlighted the statistical significance of the results, noting the substantial improvement in radiographic progression-free survival across both the BRCA1 (搜索)/2 subgroup and the broader intention-to-treat population.
The research team emphasized that this represents just the beginning of advancing precision oncology approaches in metastatic hormone-sensitive prostate cancer (搜索), with Johnson & Johnson remaining committed to transforming outcomes for patients through innovative science and collaboration.